Psychiatric Pharmacogenomics
A special issue of Genes (ISSN 2073-4425). This special issue belongs to the section "Pharmacogenetics".
Deadline for manuscript submissions: 15 September 2025 | Viewed by 29
Special Issue Editor
2. Department of Mental Health, Varisano Hospital Frankfurt Hoechst, Frankfurt am Main, Germany
Interests: pharmacogenetics; pharmacogenomics; pharmaceutical care; therapeutic drug monitoring; pharmacokinetics
Special Issue Information
Dear Colleagues,
Pharmacogenetics is becoming increasingly important in the treatment of people with psychiatric disorders. New drugs are only entering the market sporadically, and new approaches are even rarer. Pharmacogenetics can now be used to better help those affected. Numerous studies and meta-analyses exist, evidencing that patient responses and tolerability are improved when pharmacogenetics is used. Focusing on only a single gene or a single degradation pathway of drugs and psychotropic drugs has not proved to be useful. New studies must consider all the pharmacogenes involved in controlling the degradation of a drug. As such, therapeutic drug monitoring can provide valuable information here. Other factors can also influence the kinetics of a drug and must be considered (e.g., smoking status). Given the complexity of the pharmacokinetics of psychotropic drugs, interdisciplinary collaboration with clinical pharmacists is necessary to comprehensively consider all aspects and realise solutions to improve patient outcomes.
Prof. Dr. Martina Hahn
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pharmacogenetics
- pharmacogenomics
- pharmacokinetics
- therapeutic drug monitoring
- psychotropic drugs
- psychiatric pharmacogenomics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
